Periscope Capital’s Ibere Pharmaceuticals IBER Stock Holding History

Periscope Capital’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-470,395	Closed	-$4.75M	–	911
2022 Q4	$4.75M	Buy	470,395 +14,225	+3%	+$142K	0.2%	190
2022 Q3	$4.52M	Buy	456,170 +101,570	+29%	+$1M	0.13%	314
2022 Q2	$3.48M	Hold	354,600	–	–	0.09%	430
2022 Q1	$3.48M	Buy	354,600 +75,000	+27%	+$731K	0.09%	446
2021 Q4	$2.71M	Buy	279,600 +249,600	+832%	+$2.43M	0.07%	462
2021 Q3	$291K	Hold	30,000	–	–	0.01%	603
2021 Q2	$290K	Buy	+30,000	New	+$292K	0.01%	565

Periscope Capital's IBER Position: Q1 2023 in Review

Periscope Capital sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 470,395 shares — an estimated $4.75M sold.

Periscope Capital first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $4.75M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Periscope Capital reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Periscope Capital sold 470,395 Ibere Pharmaceuticals shares in Q1 2023, an estimated $4.75M.
Periscope Capital first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Periscope Capital's Ibere Pharmaceuticals position peaked at $4.75M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.